View Item 

Show simple item record

12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients

dc.contributor.authorTedesco-Silva, Helioen_US
dc.contributor.authorVitko, Stefanen_US
dc.contributor.authorPascual, Julioen_US
dc.contributor.authorEris, Josetteen_US
dc.contributor.authorMagee, John C.en_US
dc.contributor.authorWhelchel, Johnen_US
dc.contributor.authorCivati, Giovannien_US
dc.contributor.authorCampbell, Scotten_US
dc.contributor.authorAlves-Filho, Gentilen_US
dc.contributor.authorBourbigot, Bernarden_US
dc.contributor.authorGarcia, Valter Duroen_US
dc.contributor.authorLeone, Johnen_US
dc.contributor.authorEsmeraldo, Ronaldoen_US
dc.contributor.authorRigotti, Paoloen_US
dc.contributor.authorCambi, Vincenzoen_US
dc.contributor.authorHaas, Tomasen_US
dc.date.accessioned2010-06-01T21:35:40Z
dc.date.available2010-06-01T21:35:40Z
dc.date.issued2007-01en_US
dc.identifier.citationTedesco-Silva, Helio; Vitko, Stefan; Pascual, Julio; Eris, Josette; Magee, John C.; Whelchel, John; Civati, Giovanni; Campbell, Scott; Alves-Filho, Gentil; Bourbigot, Bernard; Garcia, Valter Duro; Leone, John; Esmeraldo, Ronaldo; Rigotti, Paolo; Cambi, Vincenzo; Haas, Tomas (2007). "12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients." Transplant International 20(1): 27-36. <http://hdl.handle.net/2027.42/74645>en_US
dc.identifier.issn0934-0874en_US
dc.identifier.issn1432-2277en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74645
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17181650&dopt=citationen_US
dc.format.extent516142 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rightsJournal compilation 2007 European Society for Organ Transplantationen_US
dc.subject.otherCyclosporineen_US
dc.subject.otherEfficacyen_US
dc.subject.otherEverolimusen_US
dc.subject.otherRenal Transplanten_US
dc.subject.otherSafetyen_US
dc.title12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipientsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum5  Division of Transplant Surgery, University of Michigan Medical Center, Ann Arbor, MI, USAen_US
dc.contributor.affiliationother1  Division of Nephrology, Hospital do Rim e Hipertensao, Sao Paolo, Brazilen_US
dc.contributor.affiliationother2  Transplant Centre IKEM, Prague, Czech Republicen_US
dc.contributor.affiliationother3  Servicio de Nefrologia, Hospital Ramon y Cajal, Madrid, Spainen_US
dc.contributor.affiliationother4  Royal Prince Alfred Hospital, Sydney, Australiaen_US
dc.contributor.affiliationother6  Organ Transplant Services, Piedmont Hospital, Atlanta, GA, USAen_US
dc.contributor.affiliationother7  Divisione Nefrologia e Dialisi, Az. Osp. Niguarda Ca’ Granda, Milano, Italyen_US
dc.contributor.affiliationother8  Princess Alexandra Hospital, Brisbane, Qld, Australiaen_US
dc.contributor.affiliationother9  Hospital das ClÍnicas – UNICAMP, Campinas, SP, Brazilen_US
dc.contributor.affiliationother10  Service de Nephrologie, CHU, HÔpital Cavale Blanche, Brest, Franceen_US
dc.contributor.affiliationother11  Santa Casa de MisericÓridia de Porto Alegre, RS, Brazilen_US
dc.contributor.affiliationother12  Lifelink Transplant Institute, Tampa General Hospital, Tampa, FL, USAen_US
dc.contributor.affiliationother13  Hospital Geral de Fortaleza – Setor de Transplante Renal, Fortaleza, Ceara, Brazilen_US
dc.contributor.affiliationother14  Department of Medical and Surgical Sciences, Policlinico Hospital, Padua, Italyen_US
dc.contributor.affiliationother15  Department of Medicine and Nephrology, Maggiore Hospital, Parma, Italyen_US
dc.contributor.affiliationother16  Business Unit Transplantation, Novartis Pharma AG, Basel, Switzerlanden_US
dc.identifier.pmid17181650en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74645/1/j.1432-2277.2006.00414.x.pdf
dc.identifier.doi10.1111/j.1432-2277.2006.00414.xen_US
dc.identifier.sourceTransplant Internationalen_US
dc.identifier.citedreferenceHariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311.en_US
dc.identifier.citedreferencePascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580.en_US
dc.identifier.citedreferenceNashan B. Early clinical experience with a novel rapamycin derivative. Ther Drug Monit 2002; 24: 53.en_US
dc.identifier.citedreferenceSehgal S. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995; 17: 660.en_US
dc.identifier.citedreferenceSchuler W, Cottens S, HÄberlin B, et al. SDZ RAD, a new rapamycin derivative: pharmacologic properties in vitro and in vivo. Transplantation 1996; 64: 36.en_US
dc.identifier.citedreferenceHausen B, Boeke K, Berry GJ, Segarra IT, Christians U, Morris RE. Suppression of acute rejection in allogenic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine. J Heart Lung Transplant 1999; 18: 150.en_US
dc.identifier.citedreferenceSchuurman H-J, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 1997; 64: 32.en_US
dc.identifier.citedreferenceSerkova N, Hausen B, Berry GJ, et al. Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine. J Pharmacol Exp Ther 2000; 294: 323.en_US
dc.identifier.citedreferenceHausen B, Boeke K, Berry GJ, et al. Coadministration of Neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability by staggered simultaneous treatment. Transplantation 1999; 67: 956.en_US
dc.identifier.citedreferenceVitko S, Margreiter R, Weimar W, et al. the RAD 201 Study Group. International, double-blind, parallel-group study of the safety and efficacy of Certican TM (RAD) versus mycophenolate mofetil (MMF) in combination with Neoral ® and steroids. Am J Transplant 2001; 1 ( Suppl. 1 ): 474.en_US
dc.identifier.citedreferenceKaplan B, Tedesco-Silva H, Mendez R, et al. the RAD 251 Study Group. Abstract 1339. North/South American, double-blind, parallel group study of the safety and efficacy of Certican TM (RAD) versus mycophenolate mofetil (MMF) in combination with Neoral ® and corticosteroids. Am J Transplant 2001; 1 ( Suppl. 1 ): 475.en_US
dc.identifier.citedreferenceThervet E, Pfeffer P, Scolari MP, et al. Clinical outcomes during the first 3 months post-transplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion (Neoral ® ). Transplantation 2003; 76: 903.en_US
dc.identifier.citedreferenceVitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 626.en_US
dc.identifier.citedreferenceKovarik JM, Hsu CH, McMahon L, Berthier S, Rordorf C. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther 2001; 70: 247.en_US
dc.identifier.citedreferenceNankivell B, Gruenewald SM, Allen RD, Chapman JR. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683.en_US
dc.identifier.citedreferenceCockcroft D, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.en_US
dc.identifier.citedreferenceDavidson J, Wilkinson A, Dantal J et al. New onset diabetes after transplantation: 2003 international consensus guidelines. Transplantation 2003; 75: S3.en_US
dc.identifier.citedreferenceStefoni S, Midtved K, Cole E, et al. Efficacy and safety outcomes among de novo renal transplant recipients managed by C2 monitoring of cyclosporine A microemulsion: results of a 12-month, randomized, multicenter study. Transplantation 2005; 79: 577.en_US
dc.identifier.citedreferenceNashan B, Curtis J, Ponticelli C, et al. Everolimus and reduced exposure cyclosporine in de novo renal transplant recipients: a 3-year phase II, randomized, multicenter, open-label study. Transplantation 2004; 78: 1332.en_US
dc.identifier.citedreferenceLawen J, Davies EA, Mourad G, et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation 2003; 75: 37.en_US
dc.identifier.citedreferenceLebranchu Y, Bridoux F, Buchler M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002; 2: 48.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1432-2277.2006.00414.x.pdf
Size:
504.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.